Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus

Bristol-Myers Squibb Product Deucravacitinib
Bristol-Myers Squibb (BMY) product deucravacitinib has demonstrated positive results from the Phase 2 PAISLEY study in comparison to placebo in patients with moderate to severe systemic lupus erythematosus (SLE).

The study met the primary endpoint.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. The product has a unique mechanism of . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.